Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin:a randomised, double-blind, placebo-controlled trial

Bailey, Clifford J.; Gross, Jorge L.; Pieters, Anne; Bastien, Arnaud and List, James F. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin:a randomised, double-blind, placebo-controlled trial. The Lancet, 375 (9733), pp. 2223-2233.

Abstract

Correction of hyperglycaemia and prevention of glucotoxicity are important objectives in the management of type 2 diabetes. Dapagliflozin, a selective sodium-glucose cotransporter-2 inhibitor, reduces renal glucose reabsorption in an insulin-independent manner. We assessed the efficacy and safety of dapagliflozin in patients who have inadequate glycaemic control with metformin.

Publication DOI: https://doi.org/10.1016/S0140-6736(10)60407-2
Divisions: Life & Health Sciences > Biomedical Sciences research group
Life & Health Sciences > Biosciences
Life & Health Sciences > Applied Health Research Group
Life & Health Sciences
Related URLs:
Additional Information: Copyright 2010 Elsevier Ltd. All rights reserved.
Uncontrolled Keywords: adult,blood glucose,type 2 diabetes mellitus,double-blind method,female,glucosides,glycosylated hemoglobin A,humans,hypoglycemic agents,male,metformin,middle aged,sodium-glucose transporter 2,Medicine(all)

Download

Full text not available from this repository.

Export / Share Citation


Statistics

Additional statistics for this record